Adimmune Corporation (4142.TW)
TWD 18.85
(-3.83%)
TWD 18.85
(-3.83%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.91 Billion TWD | -8.7% |
| 2022 | 2.1 Billion TWD | 65.09% |
| 2021 | 1.27 Billion TWD | -3.19% |
| 2020 | 1.31 Billion TWD | -48.07% |
| 2019 | 2.53 Billion TWD | -3.14% |
| 2018 | 2.61 Billion TWD | -4.08% |
| 2017 | 2.72 Billion TWD | -3.02% |
| 2016 | 2.8 Billion TWD | 116.07% |
| 2015 | 1.3 Billion TWD | 10.14% |
| 2014 | 1.18 Billion TWD | -35.97% |
| 2013 | 1.84 Billion TWD | -4.03% |
| 2012 | 1.92 Billion TWD | 10.75% |
| 2011 | 1.73 Billion TWD | 73.37% |
| 2010 | 1 Billion TWD | -12.01% |
| 2009 | 1.13 Billion TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 1.78 Billion TWD | -4.51% |
| 2024 Q1 | 1.86 Billion TWD | -0.03% |
| 2023 Q2 | 2.01 Billion TWD | -4.19% |
| 2023 Q4 | 1.91 Billion TWD | -4.38% |
| 2023 Q1 | 2.09 Billion TWD | -0.13% |
| 2023 FY | 1.91 Billion TWD | -8.7% |
| 2023 Q3 | 2 Billion TWD | -0.22% |
| 2022 Q3 | 2.18 Billion TWD | -0.01% |
| 2022 FY | 2.1 Billion TWD | 65.09% |
| 2022 Q1 | 1.27 Billion TWD | 0.29% |
| 2022 Q2 | 2.18 Billion TWD | 71.56% |
| 2022 Q4 | 2.1 Billion TWD | -4.04% |
| 2021 FY | 1.27 Billion TWD | -3.19% |
| 2021 Q3 | 1.31 Billion TWD | -0.14% |
| 2021 Q4 | 1.27 Billion TWD | -3.1% |
| 2021 Q2 | 1.31 Billion TWD | -0.08% |
| 2021 Q1 | 1.31 Billion TWD | 0.13% |
| 2020 Q2 | 1.24 Billion TWD | -20.71% |
| 2020 Q3 | 1.04 Billion TWD | -16.1% |
| 2020 Q4 | 1.31 Billion TWD | 25.97% |
| 2020 FY | 1.31 Billion TWD | -48.07% |
| 2020 Q1 | 1.56 Billion TWD | -38.03% |
| 2019 Q1 | 2.65 Billion TWD | 1.52% |
| 2019 Q2 | 2.61 Billion TWD | -1.39% |
| 2019 Q3 | 2.6 Billion TWD | -0.3% |
| 2019 FY | 2.53 Billion TWD | -3.14% |
| 2019 Q4 | 2.53 Billion TWD | -2.96% |
| 2018 Q4 | 2.61 Billion TWD | -3.06% |
| 2018 FY | 2.61 Billion TWD | -4.08% |
| 2018 Q1 | 2.72 Billion TWD | 0.12% |
| 2018 Q2 | 2.69 Billion TWD | -1.3% |
| 2018 Q3 | 2.69 Billion TWD | 0.13% |
| 2017 Q2 | 2.78 Billion TWD | -0.65% |
| 2017 Q1 | 2.8 Billion TWD | -0.18% |
| 2017 FY | 2.72 Billion TWD | -3.02% |
| 2017 Q4 | 2.72 Billion TWD | -1.29% |
| 2017 Q3 | 2.75 Billion TWD | -0.93% |
| 2016 FY | 2.8 Billion TWD | 116.07% |
| 2016 Q4 | 2.8 Billion TWD | 115.08% |
| 2016 Q3 | 1.3 Billion TWD | 0.0% |
| 2016 Q2 | 1.3 Billion TWD | 0.46% |
| 2016 Q1 | 1.3 Billion TWD | 0.0% |
| 2015 Q2 | 1.3 Billion TWD | 13.9% |
| 2015 Q3 | 1.3 Billion TWD | 0.0% |
| 2015 FY | 1.3 Billion TWD | 10.14% |
| 2015 Q4 | 1.3 Billion TWD | 0.0% |
| 2015 Q1 | 1.14 Billion TWD | -3.3% |
| 2014 Q1 | 1.88 Billion TWD | 2.15% |
| 2014 FY | 1.18 Billion TWD | -35.97% |
| 2014 Q4 | 1.18 Billion TWD | -31.04% |
| 2014 Q2 | 1.78 Billion TWD | -5.39% |
| 2014 Q3 | 1.71 Billion TWD | -3.94% |
| 2013 Q2 | 1.9 Billion TWD | -1.0% |
| 2013 Q4 | 1.84 Billion TWD | -1.04% |
| 2013 FY | 1.84 Billion TWD | -4.03% |
| 2013 Q1 | 1.92 Billion TWD | 0.0% |
| 2013 Q3 | 1.86 Billion TWD | -2.05% |
| 2012 Q4 | 1.92 Billion TWD | -0.99% |
| 2012 Q3 | 1.94 Billion TWD | 5.72% |
| 2012 Q1 | 1.76 Billion TWD | 1.84% |
| 2012 FY | 1.92 Billion TWD | 10.75% |
| 2012 Q2 | 1.83 Billion TWD | 3.9% |
| 2011 Q4 | 1.73 Billion TWD | 13.03% |
| 2011 Q2 | 1.17 Billion TWD | 0.0% |
| 2011 Q3 | 1.53 Billion TWD | 30.65% |
| 2011 FY | 1.73 Billion TWD | 73.37% |
| 2010 FY | 1 Billion TWD | -12.01% |
| 2010 Q4 | 1 Billion TWD | 0.0% |
| 2009 FY | 1.13 Billion TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Apex Biotechnology Corp. | 116.19 Million TWD | -1550.65% |
| Sinphar Pharmaceutical Co.,Ltd. | 1.49 Billion TWD | -28.367% |
| Panion & Bf Biotech Inc. | 125.41 Million TWD | -1429.277% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 700 Million TWD | -173.998% |
| GenMont Biotech Incorporation | 20.11 Million TWD | -9436.54% |
| Abnova (Taiwan) Corporation | 2.6 Million TWD | -73640.446% |
| Tanvex BioPharma, Inc. | 1.56 Billion TWD | -22.295% |
| Polaris Group | 352.96 Million TWD | -443.387% |
| Energenesis Biomedical CO.,LTD. | - TWD | -Infinity% |
| UnicoCell Biomed Co., Ltd. | 68.23 Million TWD | -2710.817% |
| PELL Bio-Med Technology Co. Ltd. | 147.46 Million TWD | -1200.623% |